Development of Small Molecule Drugs Targeting Immune Checkpoints

Overview

Journal Cancer Biol Med

Specialty Oncology

Date 2024 May 10

PMID 38727005

Authors

Luoyi Chen

Xinchen Zhao

Xiaowei Liu

Yujie Ouyang

Chuan Xu

Ying Shi

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors (ICIs) are used to relieve and refuel anti-tumor immunity by blocking the interaction, transcription, and translation of co-inhibitory immune checkpoints or degrading co-inhibitory immune checkpoints. Thousands of small molecule drugs or biological materials, especially antibody-based ICIs, are actively being studied and antibodies are currently widely used. Limitations, such as anti-tumor efficacy, poor membrane permeability, and unneglected tolerance issues of antibody-based ICIs, remain evident but are thought to be overcome by small molecule drugs. Recent structural studies have broadened the scope of candidate immune checkpoint molecules, as well as innovative chemical inhibitors. By way of comparison, small molecule drug-based ICIs represent superior oral bioavailability and favorable pharmacokinetic features. Several ongoing clinical trials are exploring the synergetic effect of ICIs and other therapeutic strategies based on multiple ICI functions, including immune regulation, anti-angiogenesis, and cell cycle regulation. In this review we summarized the current progression of small molecule ICIs and the mechanism underlying immune checkpoint proteins, which will lay the foundation for further exploration.

References

Johnson D, McDonnell W, Gonzalez-Ericsson P, Al-Rohil R, Mobley B, Salem J . A case report of clonal EBV-like memory CD4 T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med. 2019; 25(8):1243-1250. PMC: 6689251. DOI: 10.1038/s41591-019-0523-2. View

Fox E, Oliver T, Rowe M, Thomas S, Zakharia Y, Gilman P . Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer. Front Oncol. 2018; 8:370. PMC: 6141803. DOI: 10.3389/fonc.2018.00370. View

Anderson A, Joller N, Kuchroo V . Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity. 2016; 44(5):989-1004. PMC: 4942846. DOI: 10.1016/j.immuni.2016.05.001. View

Sui X, Niu X, Zhou X, Gao Y . Peptide drugs: a new direction in cancer immunotherapy. Cancer Biol Med. 2023; 21(3). PMC: 10976324. DOI: 10.20892/j.issn.2095-3941.2023.0297. View

Jiang J, Zou X, Liu Y, Liu X, Dong K, Yao X . Simultaneous Determination of a Novel PD-L1 Inhibitor, IMMH-010, and Its Active Metabolite, YPD-29B, in Rat Biological Matrices by Polarity-Switching Liquid Chromatography-Tandem Mass Spectrometry: Application to ADME Studies. Front Pharmacol. 2021; 12:677120. PMC: 8256334. DOI: 10.3389/fphar.2021.677120. View

Ding Z, Wang S, Shi Y, Fei X, Cheng B, Lu Y . Discovery of Novel d-(+)-Biotin-Conjugated Resorcinol Dibenzyl Ether-Based PD-L1 Inhibitors for Targeted Cancer Immunotherapy. J Med Chem. 2023; 66(15):10364-10380. DOI: 10.1021/acs.jmedchem.3c00479. View

Park E, Song K, Kim D, Lee M, Manh N, Kim H . 2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPα Checkpoint. ACS Med Chem Lett. 2022; 13(9):1459-1467. PMC: 9465712. DOI: 10.1021/acsmedchemlett.2c00256. View

Liu X, Song J, Zhang H, Liu X, Zuo F, Zhao Y . Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell. 2023; 41(2):272-287.e9. DOI: 10.1016/j.ccell.2023.01.001. View

Agostinetto E, Eiger D, Lambertini M, Ceppi M, Bruzzone M, Ponde N . Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. Eur J Cancer. 2021; 148:76-91. DOI: 10.1016/j.ejca.2021.01.043. View

10.

Reardon D, Desjardins A, Rixe O, Cloughesy T, Alekar S, Williams J . A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma. Invest New Drugs. 2020; 38(6):1784-1795. DOI: 10.1007/s10637-020-00950-1. View

11.

Kondo Y, Ohno T, Nishii N, Harada K, Yagita H, Azuma M . Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma. Oral Oncol. 2016; 57:54-60. DOI: 10.1016/j.oraloncology.2016.04.005. View

12.

Hoelder S, Clarke P, Workman P . Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol. 2012; 6(2):155-76. PMC: 3476506. DOI: 10.1016/j.molonc.2012.02.004. View

13.

Okazaki T, Honjo T . PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007; 19(7):813-24. DOI: 10.1093/intimm/dxm057. View

14.

Blando J, Sharma A, Higa M, Zhao H, Vence L, Yadav S . Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019; 116(5):1692-1697. PMC: 6358697. DOI: 10.1073/pnas.1811067116. View

15.

Lv Q, Zhou F, Liu X, Zhi L . Artificial intelligence in small molecule drug discovery from 2018 to 2023: Does it really work?. Bioorg Chem. 2023; 141:106894. DOI: 10.1016/j.bioorg.2023.106894. View

16.

Sharpe A . Introduction to checkpoint inhibitors and cancer immunotherapy. Immunol Rev. 2017; 276(1):5-8. PMC: 5362112. DOI: 10.1111/imr.12531. View

17.

Fenalti G, Villanueva N, Griffith M, Pagarigan B, Lakkaraju S, Huang R . Structure of the human marker of self 5-transmembrane receptor CD47. Nat Commun. 2021; 12(1):5218. PMC: 8410850. DOI: 10.1038/s41467-021-25475-w. View

18.

Hu Z, Yu P, Du G, Wang W, Zhu H, Li N . PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice. PLoS One. 2020; 15(3):e0228339. PMC: 7098565. DOI: 10.1371/journal.pone.0228339. View

19.

Burgess T, Amason J, Rubin J, Duveau D, Lamy L, Roberts D . A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology. PLoS One. 2020; 15(4):e0226661. PMC: 7117682. DOI: 10.1371/journal.pone.0226661. View

20.

Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G . Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019; 18(6):463-477. PMC: 6552674. DOI: 10.1038/s41573-019-0024-5. View